Regulation of CD80/B7-1 and CD86/B7-2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition

European Journal of Immunology

Volumn 28, Issue 1, 1998, Pages 90-103

  Costello, Régis T ^a   Mallet, Françoise ^a   Sainty, Danielle ^a   Maraninchi, Dominique ^a   Gastaut, Jean Albert ^a   Olive, Daniel ^a,b,c  

^a AIX MARSEILLE UNIVERSITY   (France)

^b INSERM   (France)

^c INSTITUT PAOLI CALMETTES   (France)

Author keywords

Acute myeloid leukemia; Antigen presenting cell; CD80; CD86; Mixed lymphocyte reaction

Indexed keywords

ALLOANTIGEN; B7 ANTIGEN; CD4 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; GLYCOPROTEIN GP 39; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2; INTERLEUKIN 4;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HELPER CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; MALE; MIXED LYMPHOCYTE REACTION; MONOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTIGEN PRESENTATION; ANTIGENS, CD; ANTIGENS, CD40; ANTIGENS, CD80; ANTIGENS, CD86; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; LEUKEMIA, MONOCYTIC, ACUTE; LEUKEMIA, MYELOMONOCYTIC, ACUTE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; LYMPHOKINES; MEMBRANE GLYCOPROTEINS; MONOCYTES; TUMOR CELLS, CULTURED;

EID: 0031985295     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1521-4141(199801)28:01<90::AID-IMMU90>3.0.CO;2-5     Document Type: Article

References (79)

1. Minden, M., Imrie, K. and Keating, A., Acute leukemia in adults. Curr. Opin. Hematol. 1996. 3: 259-265.
2. Antin, J. H., Graft-versus leukemia: no longer an epiphenomenon. Blood 1993. 82: 2273-2277.
3. Gale, R. P., Horowitz, M. M., Ash, R. C., Champlin, R. E., Goldman, J. M., Rimm, A. A., Ringden, O., Stone, J. A. and Bortin, M. M., Identical-twin bone marrow transplants for leukemia. Ann. Intern. Med. 1994. 120: 646-652.
4. Horowitz, M. M., Gale, R. P., Sondel, M. M., Goldman, J. M., Kersey, J., Kolb, H. J., Rimm, A. A., Ringden, O., Rozman, C. and Speck, B., Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990. 75: 555-562.
5. Weiden, P. L., Sullivan, K. M. and Flournoy, N., Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic bone marrow transplantation. N. Engl. J. Med. 1981. 304: 1529-1533.
6. Goldman, J. M., Gale, R. P., Horowitz, M. M., Biggs, J. C., Champlin, R. E., Gluckman, E., Hoffmann, R. G., Jacobsen, S. J., Marmont, A. M. and McGlave, P. B., Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann. Intern. Med. 1988. 108: 806-814.
7. van Rhee, F. and Kolb, H.-J., Donor leukocyte transfusions for leukemic relapse. Curr. Opin. Immunol. 1995. 2: 423-426.
8. Kolb, H. J., Mittermueller, J., Clemm, C., Holler, E., Ledderose, G., Brehm, G., Heim, M. and Wilmans, W., Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990. 76: 2462-2465.
9. van Rhee, F., Lin, F., Cullis, J. O., Spencer, A., Cross, N. C., Chase, A., Garicochea, B., Bungey, J., Barrett, J. and Goldman, J. M., Relapse of chronic myeloid leukemia after allogeneic bone marrow transplantat: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994. 83: 3377-3383.
10. Van Pel, A., van der Bruggen, P. and Coulie, P. G., Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol. Rev. 1995. 145: 229-250.
11. Pardoll, D. M., Tumour antigens. A new look for the 1990s. Nature 1994. 369: 67-71.
12. Boon, T., Cerottini, J. C., Eynde, B., Bruggen, P. and Van Pel, A., Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 1994. 12: 337-365.
13. Bocchia, M., Wentworth, P. A., Southwood, S., Sidney, J., McGraw, K., Scheinberg, D. A. and Sette, A., Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood 1995. 85: 2680-2684.
14. Bocchia, M., Korontsvit, T., Xu, Q., Mackinnon, S., Yang, S. Y., Sette, A. and Scheinberg, D. A., Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 1996. 87: 3587-3592.
15. Pawelec, G., Max, H., Halder, T., Bruserud, O., Merl, A., da Silva, P. and Kalbacher, P., BCR/ABL leukemia oncogene fusion peptides selectively binds to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors. Blood 1996. 88: 2118-2124.
16. Coleman, S., Fisher, J., Hoy, T., Burnett, A. K. and Lim, S. H., Autologous MHC-dependent leukaemiareactive T lymphocytes in a patient with chronic myeloid leukaemia. Leukemia 1996. 10: 483-487.
17. Gambacorti-Passerini, C., Grignani, F., Arienti, F., Pandolfi, P. P., Pelicci, P. G. and Parmiani, G., Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells. Blood 1993. 81: 1369-1375.
18. Olive, D., Pages, F., Klasen, S., Battifora, M., Costello, R., Nunes, J., Truneh, A., Ragueneau, M., Martin, Y., Imbert, J., Birg, F., Mawas, C., Bagnasco, M. and Cerdan, C., Stimulation via the CD28 molecule. Regulation of signaling, cytokine production and cytokine receptor expression. Fundam. Clin. Immunol. 1994. 2: 185-197.
19. June, C. H., Bluestone, J. A., Nadler, L. M. and Thompson, C. B., The B7 and CD28 receptor families. Immunol. Today 1994. 15: 321-331.
20. Schultze, J., Nadler, L. M. and Gribben, J. G., B7-mediated costimulation and the immune response. Blood Rev. 1996. 10: 111-127.
21. Guinan, E. C., Gribben, J. G., Boussiotis, V. A., Freeman, G. J. and Nadler, L. M., Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 1994. 84: 3261-3282.
22. Engel, P. and Tedder, T. F., New CD from the B cell section of the Fifth International Workshop on Human Leukocyte Differentiation Antigens. Leuk. Lymphoma 1994. 13: 61-64.
23. Freeman, G. J., Gribben, J. G., Boussiotis, V. A., Ng, J. W., Restivo, V. A. Jr., Lombard, L. A., Gray, G. S. and Nadler, L. M., Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Sciences 1993. 262: 909-911.
24. Engel, P., Gribben, J. G., Freeman, G. J., Zhou, L. J., Nozawa, Y., Abe, M., Nadler, L. M., Wakasa, H. and Tedder, T. F., The B7-2 (B70) costimulatory molecule expressed by monocytes and activated B lymphocytes is the CD86 differentiation antigen. Blood 1994. 84: 1402-1407.
25. Caux, C., Vanbervliet, B., Massacrier, C. M., Azuma, K., Okumura, L., Lanier, L. and Banchereau, J., B70/ B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells. J. Exp. Med. 1994. 180: 1841-1847.
26. Matulonis, U. A., Dosiou, C., Lamont, C., Freeman, G. J., Mauch, P., Nadler, L. M. and Griffin, J. D., Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood 1995. 85: 2507-2515.
27. Matulonis, U., Dosiou, C., Freeman, G., Lamont, C., Mauch, P., Nadler, L. M. and Griffin, J. D., B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct. J. Immunol. 1996. 156: 1126-1131.
28. Dunussi-Joannopoulos, K., Weinstein, H. J., Nickerson, P. W., Strom, T. B., Burakoff, S. J., Croop, J. M. and Arceci, R. J., Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML. Blood 1996. 87: 2938-2946.
29. Delabie, J., Ceuppens, J. L., Vandenberghe, P., de Boer, M., Coorevits, L. and De Wolf-Peeters, C., The B7/BB1 antigen is expressed by Reed-Sternberg cells of Hodgkin's disease and contributes to the stimulating capacity of Hodgkin's disease-derived cell lines. Blood 1993. 82: 2845-2852.
30. Munro, J. M., Freedman, A. S., Aster, J. C., Gribben, J. G., Lee, N. C., Rhynhart, K. K., Banchereau, J. and Nadler, L. M., In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease. Blood 1994. 83: 793-798.
31. Delabie, J., Chan, W. C., Weisenburger, D. D. and De Wolf-Peeters, C., The antigen-presenting cell function of Reed-Sternberg cells. Leuk. Lymphoma 1995. 18: 35-40.
32. Van den Hove, L. E., Van Goll, S. W., Vandenberghe, P., Bakkus, M., Thielemans, K., Boogaerts, M. A. and Ceuppens, J. L., CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by up-regulation of CD80 and CD86 costimulatory molecules. Leukemia 1997. 11: 572-580.
33. Schultze, J. L., Cardoso, A. A., Freeman, G. J., Seamon, M. J., Daley, J., Pinkus, G. S., Gribben, J. G. and Nadler, L. M., Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc. Natl. Acad. Sci. USA 1995. 92: 8200-8204.
34. Freeman, G. J., Freedman, A. S., Segil, J. M., Lee, G., Whitman, J. F. and Nadler, L. M., B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J. Immunol. 1989. 143: 2714-2722.
35. Plumas, J., Chaperot, L., Jacob, M. C., Molens, J. P., Giroux, C., Sotto, J. J. and Bensa, J. C., Malignant B lymphocytes form non-Hodgkin's lymphoma induce allogeneic proliferative and cytotoxic T cell responses in primary mixed lymphocyte cultures: an important role of costimulatory molecules CD80 (B7-1) and CD86 (B7-2) in stimulation by tumor cells. Eur. J. Immunol. 1995. 25: 3332-3341.
36. Shamash, J., Davies, D. C., Salam, A., Rohatiner, A. Z., Young, B. D. and Lister, T. A., Induction of CD80 expression in low-grade B cell lymphoma - a potential immunotherapeutic target. Leukemia 1995. 9: 1349-1352.
37. Hirano, N., Takahashi, T., Ohtaka, S., Hirashima, K., Emi, N., Saito, K., Hirano, M., Shinoara, K., Takeuchi, M., Taketazu, F., Tsunoda, S., Ogura, M., Omine, M., Saito, T., Yazaki, Y., Ueda, R. and Hirai, H., Expression of costimulatory molecules in human leukemias. Leukemia 1996. 10: 1168-1176.
38. Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D. A. G., Gralnick, H. and Sultan, C., Proposed revised criteria for the classification of acute myeloid leukemia. Ann. Intern. Med. 1985. 103: 626-629.
39. Catovsky, D. and Matutes, E., The classification of acute leukaemia. Leukemia 1992. 6: 1-6.
40. Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D. A. G., Gralnick, H. and Sultan, C., Proposal for the recognition of minimally differentiated acute myeloid leukaemia. Br. J. Haematol. 1991. 78: 325-329.
41. Peters, J. H., Gieseler, R., Thiele, B. and Steinbach, F., Dendritic cells: from ontogenic orphans to myelomonocytic descendants, Immunol. Today 1996. 17: 273-278.
42. Townsend, S. E., Su, F. W., Atherton, J. M. and Allison, J. P., Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res. 1994. 54: 6477-6483.
43. Schwartz, R. H., Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992. 71: 1065-1068.
44. Gimmi, C. D., Freeman, G. J., Gribben, J. G., Sugita, K., Freedman, A. S., Morimoto, C. and Nadler, L. M., B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. Proc. Natl. Acad. Sci. USA 1991. 88: 6575-6579.
45. Azuma, M., Ito, D., Yagita, H., Okumura, K., Phillips, J. H., Lanier, L. L. and Somoza, C., B70 antigen is a second ligand for CTLA-4 and CD28. Nature 1993. 366: 76-79.
46. Creery, D., Diaz-Mitoma, F., Filion, L. and Kumar, A., Differential modulation of B7-1 and B7-2 isoform expression on human monocytes by cytokines which influence the development of T helper cell phenotype. Eur. J. Immunol. 1996. 26: 1273-1277.
47. Freedman, A. S., Freeman, G. J., Rhynhart, K. and Nadler, L. M., Selective induction of B7/BB-1 on interferon-gamma stimulated monocytes: a potential mechanism for amplification of T cell activation through the CD28 pathway. Cell Immunol. 1991. 137: 429-437.
48. Banchereau, J., Bazan, F., Blanchard, D., Briěre, F., Galizzi, J. P., Van Kooten, C., Liu, Y. J., Rousset, F. and Saeland, S., The CD40 antigen and its ligand. Annu. Rev. Immunol. 1994. 12: 881-992.
49. Ranheim, E. A. and Kipps, T. J., Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J. Exp. Med. 1993. 177: 925-935.
50. Gruss, H. J., Hirschstein, D., Wright, B., Ulrich, D., Caligiuri, M. A., Barcos, M., Strockbine, L., Armitage, R. J. and Dower, S. K., Expression and function of CD40 on Hodgkin and Reed-Sternberg cells and the possible relevance for Hodgkin's disease. Blood 1994. 84: 2305-2314.
51. Alderson, M. R., Armitage, R. J., Tough, T. W., Strockbine, L., Fanslow, W. C. and Spriggs, M. K., CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40. J. Exp. Med. 1993. 178: 669-674.
52. Boussiotis, V. A., Freeman, G. J., Gribben, J. G. and Nadler, L. M., The critical role of CD28 signaling in the prevention of human T-cell anergy. Res. Immunol. 1995. 146: 140-149.
53. Boussiotis, V. A., Freeman, G. J., Gray, G., Gribben, J. and Nadler, L. M., B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance. J. Exp. Med. 1993. 178: 1753-1763.
54. Gribben, J. G., Guinan, E. C., Boussiotis, V. A., Ke, X. Y., Linsley, L., Sieff, C., Gray, G. S., Freeman, G. J. and Nadler, L. M., Complete blockade of B7 familymediated costimulation is necessary to induce human alloantigen-specific anergy: a method to ameliorate graft-versus-host disease and extend the donor pool. Blood 1996. 87: 4887-4893.
55. Freeman, G. J., Boussiotis, V. A., Anumanthan, A., Bernstein, G. M., Ke, X. Y., Rennert, P. D., Gray, G. S., Gribben, J. G. and Nadler, L. M., B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity 1995. 2: 523-532.
56. Lenschow, D. J., Ho, S. C., Sattar, H., Rhee, L., Gray, G., Nabavi, N., Herald, K. C. and Bluestone, J. A., Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J. Exp. Med. 1995. 181: 1145-1155.
57. Kuchroo, V. K., Das, M. P., Brown, J. A., Ranger, A. M., Zamvil, S. S., Sobel, R. A., Weiner, H. L., Nabavi, N. and Glimcher, L. H., B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995. 80: 707-718.
58. Ranheim, E. A. and Kipps, T. J., Tumor necrosis factoralpha facilitates induction of CD80 (B7-1) and CD54 on human B cells by activated T cells: complex regulation by IL-4, IL-10, and CD40L. Cell. Immunol. 1995. 161: 226-235.
59. Goldstein, M. D. and Watts, T. H., Identification of distinct domains in CD40 involved in B7-1 induction or growth inhibition. J. Immunol. 1996. 157: 2837-2843.
60. Shinde, S., Wu, Y., Guo, Y., Niu, Q., Xu, J., Grewal, I. Q., Flavell, R. and Liu, Y., CD40L is important for induction of, but not response to, costimulatory activity. ICAM-1 as the second costimulatory molecule rapidly up-regulated by CD40L. J. Immunol. 1996. 157: 2764-2768.
61. Harding, F. A., McArthur, J. G., Gross, J. A., Raulet, D. H. and Allison, J. P., CD28-mediated signaling Co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 1992. 356: 607-609.
62. Lenschow, D. J., Zeng, Y., Thistlethwaite, J. R., Montag, A., Brady, W., Gibson, M. G., Linsley, P. S. and Bluestone, J. A., Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA-4lg. Science 1992. 257: 789-792.
63. Turka, L. A., Linsley, P. S., Lin, H., Brady, W., Leiden, J. M., Wei, R. Q., Gibson, M. L., Zheng, X. G., Myrdal, S. and Gordon, D., T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc. Natl. Acad. Sci. USA 1992. 89: 11102-11105.
64. Gimmi, C. D., Freeman, G. J., Gribben, J. G., Gray, G. and Nadler, L. M., Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc. Natl. Acad. Sci. USA 1993. 90: 6586-6590.
65. Lin, H., Bolling, S. F., Linsley, P. S., Wei, R. Q., Gordon, D., Thompson, C. B. and Turka, L. A., Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA-4lg plus donor-specific transfusion. J. Exp. Med. 1993. 178: 1801-1806.
66. Tan, P., Anasetti, C., Hansen, J. A., Melrose, J., Brunvand, M., Bradshaw, J., Ledbetter, J. A. and Linsley, P. S., Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J. Exp. Med. 1993. 177: 165-173.
67. Boussiotis, V. A., Freeman, G. J., Griffin, J. D., Gray, G. S., Gribben, J. G. and Nadler, L. M., CD2 is involved in maintenance and reversal of human alloantigen-specific clonal anergy. J. Exp. Med. 1994. 180: 1665-1673.
68. Murakami, M., Takahashi, Y., Isashi, Y., Kon, S., Jia, W.-Y., Inobe, M., Abe, R. and Uede, T., Identification and characterization of an alternative cytotoxic T lymphocyte-associated protein 4 binding molecule on B cells. Proc. Natl. Acad. Sci. USA 1996. 93: 7838-7842.
69. Boussiotis, V. A., Freeman, G. J., Gribben, J. G., Daley, J., Gray, G. and Nadler, L. M., Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation. Proc. Natl. Acad. Sci. USA 1993. 90: 11059-11063.
70. Hahne, M., Rimoldi, D., Schröter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., Cerottini, J. C. and Tschopp, J., Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996. 274: 1363-1366.
71. O'Connell, J., O'Sullivan, G. C., Collins, J. K. and Shanahan, F., The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 1996. 184: 1075-1082.
72. Gimmi, C. D., Morrison, B. W., Mainprice, B. A., Gribben, J. G., Boussiotis, V. A., Freeman, G. J., Park, S. Y. L., Watanabe, M., Gong, J.-L., Hayes, D. F., Kufe, D. W. and Nadler, L. M., Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nature Med. 1996. 2: 1367-1370.
73. Strand, S., Hofmann, W. J., Hug, H., Müller, M., Otto, G., Strand, D., Mariani, S. M., Stremmel, W., Krammer, P. H. and Galle, P. R., Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - A mechanism of immune evasion? Nature Med. 1996. 2: 1361-1366.
74. Parmiani, G., Tumor immunity as autoimmunity: tumor antigens include normal self proteins which stimulate anergic peripheral T cells. Immunol. Today 1993. 14: 536-538.
75. Guerder, S., Meyerhoff, J. and Flavell, R., The role of the T cell stimulator B7-1 in autoimmunity and the induction and maintenance of tolerance to peripheral antigen. Immunity 1994. 1: 155-166.
76. Li, Y., Hellstrom, K. E., Newby, S. A. and Chen, L., Co-stimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors. J. Exp. Med. 1996. 183: 639-644.
77. + T cells. Eur. J. Immunol. 1993. 23: 608-613.
78. Kamoun, M., Martin, P. J., Hansen, J. A., Brown, M. A., Siadek, A. W. and Nowinski, R. C., Identification of a human T lymphocyte surface protein associated with the E-rosette receptor. J. Exp. Med. 1981. 153: 207-212.
79. SPSS User's Guide, Publication no. 6.01 SPSS Inc. PC, Chicago 1993.